Health
Lung cancer: study shows 7-year disease control with lorlatinib
Patients who completed two years of treatment without tumor progression have a 79% probability of remaining stable through the seventh year, according to updated data from the CROWN clinical trial.
You have used your 3 free reads for today
The full text of this story becomes available after the daily renewal. Sports and entertainment stay open. The paid subscription is not open yet.
Your free reads renew on 11/15/2026 at 00:00 (Brasília time).
The essentials of this story
- What happened
- Phase 3 clinical trial demonstrates prolonged efficacy of medication for ALK-mutated lung cancer.
- Who is affected
- Patients with advanced, ALK-positive non-small cell lung cancer.
- What changes
- Treatment with lorlatinib keeps the disease under control for seven years in more than half of the patients, surpassing the results of previous therapies.
Create a free account to keep reading: 3 full stories a day.
The paid subscription is not on sale yet. Free sign-up already works. Planned monthly price: R$ 9.90 (in US dollars and euros, a direct conversion at the official rate on the day you subscribe).